中金公司(03908.HK)2019年次級債券(第三期)票面利率釐定為4.12%
格隆匯11月8日丨中金公司(03908.HK)公佈,公司面向合格投資者非公開發行不超過80億元次級債券已獲得上海證券交易所《關於對中國國際金融股份有限公司非公開發行次級債券掛牌轉讓無異議的函》(上證函[2019]246號)。此次債券由中信證券股份有限公司和東吳證券股份有限公司承銷。該期債券為5年期,基礎發行規模為11億元,可超額配售不過4億元。該期債券票面利率詢價區間為3.7%-4.7%。
2019年11月7日,發行人和主承銷商在網下向機構投資者進行了票面利率詢價。根據網下機構投資者詢價結果,經發行人和主承銷商協商一致,最終確定該期次級債券發行的票面利率為4.12%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.